Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.

Shigeyoshi Iwamoto(Aichi Medical University), Hideyuki Mishima(Aichi Medical University Hospital), Shoichi Hazama(Yamaguchi University), Yasuhiro Miyake(High Energy Accelerator Research Organization), Koji Oba(The University of Tokyo), Takeshi Kato(Osaka National Hospital), Mutsumi Fukunaga(Sakai Municipal Hospital), Junichi Sakamoto(Tokai Central Hospital), Chu Matsuda(Osaka International Cancer Institute), Hiroyuki Bando(Ishikawa Prefectural Central Hospital)
PubMed
April 1, 2014
Cited by 22

Related Papers

Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer
|JAMA|2023|255
A new approach for measuring the muon anomalous magnetic moment and electric dipole moment
|Progress of Theoretical and Experimental Physics|2019|239